Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 2Brain Neoplasms 2Skin Neoplasms 1Recurrence 1Lung Neoplasms 1Kidney Neoplasms 1Health Behavior 1Child Behavior 1Carcinoma, Renal Cell 1Breast Neoplasms 1Behavior 1

Interventions

aldesleukin 15pembrolizumab 11Cyclophosphamide 9fludarabine phosphate 7fludarabine 6Nivolumab 6Interleukin-2 6atezolizumab 5Radiotherapy 5Ipilimumab 4Interferon-alpha 4Drug Therapy 4Blood Specimen Collection 4Radiosurgery 3tremelimumab 2temsirolimus 2durvalumab 2cemiplimab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Metformin 2Interleukin-12 Subunit p35 2Genistein 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Cetuximab 2zanolimumab 1vivitrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Spermine Synthase × Dermatologic × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡